Eli Lilly Hits Record High on 19% Retatrutide Weight-Loss Data
Updated
Updated · CNBC · Jun 8
Eli Lilly Hits Record High on 19% Retatrutide Weight-Loss Data
3 articles · Updated · CNBC · Jun 8
Summary
Eli Lilly shares traded at all-time highs Monday after the company presented new Retatrutide data at the American Diabetes Association meeting in New Orleans.
A 4-milligram dose of the next-generation obesity drug delivered about 19% weight loss, roughly matching the top dose of Lilly's blockbuster Zepbound.
Retatrutide is a triple agonist that adds glucagon to GLP-1 and GIP activity, a profile analysts said could improve efficacy and tolerability and widen its commercial potential.
The data strengthened investor views that Lilly is extending its lead in obesity treatments: the stock is up about 8% this year, while Novo Nordisk has fallen roughly 18%.
Lilly's broader obesity franchise now spans injectables and the Foundayo pill, as investors increasingly bet GLP-1 medicines will expand into sleep apnea, cardiovascular disease and other conditions.